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Abstract
To explore the possibility that underlying genetic susceptibility influences radiation-induced lung
injury, we studied pulmonary damage after radiation therapy for lung cancer and single nucleotide
polymorphisms implicated in radiation sensitivity. An objective radiologic method (perfusion
single photon emission computed tomography) was used to assess radiation sensitivity. An
association between single nucleotide polymorphisms in XRCC1 and BRCA1 and radiation
sensitivity of the lungs was noted.
Background—The primary objective of this study was to evaluate the association between
radiation sensitivity of the lungs and candidate single nucleotide polymorphisms (SNP) in genes
implicated in radiation-induced toxicity.
Methods—Patients with lung cancer who received radiation therapy (RT) had pre-RT and serial
post-RT single photon emission computed tomography (SPECT) lung perfusion scans. RT-
induced changes in regional perfusion were related to regional dose, which generated patient-
specific dose-response curves (DRC). The slope of the DRC is independent of total dose and the
irradiated volume, and is taken as a reflection of the patient’s inherent sensitivity to RT. DNA was
extracted from blood samples obtained at baseline. SNPs were determined by using a combination
of high-resolution melting, TaqMan assays, and direct sequencing. Genotypes from 33 SNPs in 22
genes were compared against the slope of the DRC by using the Kruskal-Wallis test for ordered
alternatives.
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Results—Thirty-nine self-reported Caucasian patients with pre-RT and ≥6 month post-RT
SPECTs, and blood samples were identified. An association between genotype and increasing
slope of the DRC was noted in G(1301) A in XRCC1 (rs25487) (P = .01) and G(3748) A in
BRCA1 (rs16942) (P = .03).
Conclusions—By using an objective radiologic assessment, polymorphisms within genes
involved in repair of DNA damage (XRCC1 and BRCA1) were associated with radiation
sensitivity of the lungs.
Keywords
Genetics; Lung toxicity; Radiation sensitivity; Single photon emission computed tomography;
Single-nucleotide polymorphism
Introduction
Radiation therapy (RT) is an important treatment modality for patients with cancer, and
approximately 50% to 60% of cancer patients will receive RT at some point during their
illness. The adverse effects of RT depend principally on the site being treated, the volume of
normal tissue irradiated, the dose per fraction, the total dose administered, and whether
chemotherapy is also being administered. However, it is also clinically apparent that some
cancer patients are more sensitive to the adverse effects of RT than are others, even when all
of the factors listed above are relatively constant. Rare hereditary disorders (eg, ataxia-
telangiectasia, Nijmegen Breakage syndrome, Fanconi anemia) suggest that genetic
differences in key genes may influence radiation sensitivity.1
Single nucleotide polymorphisms (SNPs) are DNA sequence variations, in either coding or
noncoding regions, in which a single nucleotide (adenine, guanine, thymine, and cytosine)
varies among a population. To identify genetic factors that may be contributing to radiation-
induced toxicity, SNPs in genes associated with DNA repair pathways and other radiation-
related processes have been studied. By using this candidate gene approach, some studies,
but not all,2–4 have demonstrated an association between certain SNPs and acute and long-
term adverse effects of RT. These genes include TGFB1,5–11 SOD2,12,13 XRCC1,11–14
XRCC3,13,15,16 XRCC6,16 MSH2,15 MSH3,15 ATM,17,18 p53,19 FSHR,20 ABCA1,21
IL12RB2,21 LIG4,22 and RAD51.23
Most of the endpoints studied to date have been subjective signs or symptoms reported by
the patient or provider (eg, erectile dysfunction or breast fibrosis). More objective outcomes
may be preferred when evaluating potential genetic contributors of radiation sensitivity. As
part of institutional review board–approved prospective studies at Duke University, patients
with lung cancer have undergone serial perfusion single photon emission computed
tomographies (SPECT) before and after thoracic RT. Dose-dependent changes in SPECT
lung perfusion defects after treatment provide an objective assessment of inherent radiation
sensitivity.24,25 Most of these same patients had blood samples collected and stored for
correlative studies.
We recently reported an association between a polymorphism in the promoter of the
transforming growth factor β1 gene (TGFB1) and radiation sensitivity assessed by using
radiation-induced SPECT changes.26 Herein, we assess for the possible association between
12 additional SNPs that have been associated with radiation sensitivity in previous studies,
in addition to numerous other SNPs within genes known to be involved in DNA damage
recognition and repair, which may contribute to radiation sensitivity.
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As part of institutional review board–approved prospective clinical trials at Duke University,
patients with lung cancer who were receiving definitive RT underwent a pretreatment
perfusion SPECT scan as well as serial posttreatment scans to assess radiation-induced lung
injury. Blood was drawn on several patients at baseline for correlative studies and was
stored at −80°C. Patients were included in the present analysis if they (1) underwent a pre-
RT SPECT, (2) underwent a ≥6-month post-RT SPECT, (3) had at least 1 banked blood
sample, and (4) were Caucasian. Changes in SPECT perfusion after RT largely develop
within the first 6 months after treatment with minimal changes thereafter.25,27 Only self-
reported Caucasian patients were studied because the relative allelic frequency of SNPs may
differ among ancestries.
RT Planning
Patients underwent computed tomography (CT) based 3-dimensional treatment planning by
using Plan University of North Carolina software (PLUNC). The patients either received
conventionally fractionated RT (1.8–2 Gy every day to 40–70 Gy) or accelerated RT by
using a concomitant boost.28 For the latter, the patients received 1.25 Gy twice a day to the
clinical target volume, including the primary tumor and mediastinum, usually with
anteroposterior/posteroanterior fields. The gross tumor volume received a concurrent boost
of 35 cGy twice a day with off-cord fields, thus delivering 1.6 Gy twice a day to the gross
tumor volume. After the initial 57.6 Gy, the gross tumor volume received an additional dose
at 1.6 Gy twice a day to a total dose of 73.6–86.4 Gy). Chemotherapy was administered at
the discretion of the multimodality team.
Perfusion SPECTs
SPECT lung perfusion scans were obtained after the intravenous injection of
technetium-99m–labeled macroaggregated albumin as previously described.24,29,30 The pre-
and postradiation SPECT lung images were registered to each other and to the radiation
treatment planning scan (and hence the 3-dimensional dose distribution), largely manually
with the assistance of some automatic image registration tools. The SPECT images were
translated and rotated (in 6 degrees of freedom) until the “edges” of the SPECT-defined
perfusion (the area of rapid gradient in counts per cubic centimeter) were aligned with the
CT-defined lung borders, also considering the presence of the tumor and regions of
emphysema that influence the SPECT images.31 We recognize that a perfect registration is
not possible for an elastic organ in a breathing patient. Every attempt was made to have all
of the scans and the radiation treatment delivered with the patient in a similar position. In all
cases, the registration was performed by an experienced physicist.
This multi-image registration facilitated the analysis relating changes in regional perfusion
(comparison of pre- and post-radiation SPECTs) to the regional radiation dose (from the
planning CT). After registration, the quantitative SPECT data were resampled by tri-linear
interpolation to match the spatial sampling of the planning CT data set. Within each lung
pixel, the change in regional perfusion was quantified by comparing pre- and post-radiation
SPECTs.27 For each patient, and at each dose level (D), the reduction in the percentage of
SPECT counts (compared with the pre-RT scan) was calculated as percent reductionD = 100
× (1 − postD)/preD; in which postD and preD are the percentage SPECT counts on the post-
and pre-RT scans in the region that received D Gy, respectively.27
Changes in regional perfusion after RT were related to regional radiation doses (via image
fusion), which yielded a patient-specific dose-response curve (DRC). The DRC slope is
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independent of irradiated volume and is taken as a reflection of the patient’s inherent
sensitivity to radiation. The DRC was obtained from the nontumor-bearing contralateral
lung to avoid issues related to reperfusion after treatment of central tumors. Because
SPECTs provide only relative perfusion information, the DRC was “normalized” by
assuming that absolute perfusion is unchanged in “control” regions that receive very low
doses (typically <2.5 Gy).27 The normalized percent reduction in regional perfusion, R, at
dose D, is thus32:
In which the 0 subscripts refer to the lung regions at <2.5 Gy. We recognize that
normalization may be imprecise because function in the low-dose region may increase due
to compensation. Nevertheless, this is the method that has been used in the 2 centers that
have generated DRCs, and we know of no way to correct for this possibility.
Studied SNPs
Genes of interest were selected based on peer-reviewed publications and knowledge of DNA
damage repair pathways. Each gene was reviewed on the National Center for Biotechnology
Information database. SNPs within genes with a minor allele frequency more than 0.10 in a
Caucasian population were selected for analysis. SNPs within coding regions that resulted in
a synonymous mutation (no change in amino acid) were not included. Hardy-Weinberg
equilibrium was assessed for all SNPs.
Genotyping Methods
DNA extraction was performed by using the QIAamp DNA Blood Mini Kit (Qiagen,
Germantown, MD) according to the manufacturer’s instructions. DNA was found to be of
high quality, and no samples had to be discarded secondary to impurity or degradation. SNP
genotypes were determined by using a combination of high-resolution melting (HRM)
assays, TaqMan assays, and direct DNA sequencing. Primer pairs for each SNP were
designed by using the National Center for Biotechnology Information–Primer Blast program
to create approximately 125 bp amplicons that contain each SNP. HRM assays were
performed on an Applied Biosystems 7500 Fast Real-Time polymerase chain reaction
system according to the manufacturer’s instructions and were analyzed with Applied
Biosystems HRM v2.0 software (Applied Biosystems, Foster, CA). Based on the HRM
curves, selected samples were DNA sequenced to confirm the SNP genotype by using the
Duke University DNA Analysis Facility shared resource. Predefined or custom-designed
TaqMan SNP genotyping assays were obtained from Applied Biosystems and were
performed on a 7500 Fast Real-Time polymerase chain reaction instrument according to the
manufacturer’s standard protocol by using 20-ng human genomic DNA per 20 μL assay.
Data analysis was performed by using Applied Biosystems 7500 Software v2.0.4.
Statistical Analysis
All statistical summaries and analyses were produced by using the R statistical
environment.33 The SNPs were tested for the Hardy-Weinberg equilibrium by using an
exact test34 provided by the R extension package genetics. SNPs not in Hardy-Weinberg
equilibrium were not further assessed. The association between genotype and the slope of
the DRC was tested for each SNP by using the Kruskal-Wallis equilibrium powered for
ordered alternatives.35 The implementation provided by the R extension package coin36 was
used for this purpose. The analyses for all SNPs in this study were a priori powered for
additive genetic effects. Because this was an exploratory study, the results were not adjusted
for multiple testing to minimize the risk of false negatives.
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Forty-five unrelated patients with a baseline blood sample and pre-RT and ≥6-month post-
RT SPECTs, and with usable DNA, were identified. Patients who did not self-report as
Caucasian were excluded (n = 6), which left 39 for the present analysis. The majority had a
history of smoking (92%). Patients received either conventionally fractionated RT (n = 29)
or accelerated hyperfractionated RT (n = 10), with chemotherapy administered in the
majority (82%). Chemotherapy consisted of a platinum-based doublet in all patients (96%
carboplatin and 4% cisplatin). The median total radiation dose was 66 Gy (range, 40–86.4
Gy). Patient and treatment characteristics can be found in Table 1.
All the patients underwent pre- and post-radiation SPECTs. The median time between
completing treatment and follow-up SPECT was 8 months (range, 6–17 months). The
median DRC slope was 0.38 (ie, 0.38% reduction in perfusion per Gy), with a range of
−1.14 to 1.12. There was no correlation between DRC slope and the time interval of follow-
up SPECT, consistent with our prior analyses for time intervals >6 months.25,27
Forty-three SNPs in 23 genes were initially screened. Eight SNPs had a relative minor allele
frequency of zero and were not evaluated further (rs28897686, rs28897687, and rs28897688
in BRCA1; rs2229033 in ATR; rs3730017 in NOS2; rs75521089 in HIF1A; rs28897729 in
BRCA2; and rs80233386 in RAD51). Genotyping results from 1 SNP (rs1650697 in MSH3)
were not thought to be reliable, and the results were discarded. One SNP was not in Hardy-
Weinberg equilibrium and was not assessed further (rs1801321 in RAD51). This left 33
SNPs in 22 genes for the present analysis (Table 2).
Among the 33 SNPs studied, 2 were associated with increasing slope of the SPECT DRC
(Table 3). These included rs16942 (a SNP in exon 10 of BRCA1) (P = .03) and rs25487 (a
SNP in exon 10 of XRCC1) (P = .01) (Figure 1). None of the other studied SNPs were
statistically significant (Table 3). As both XRCC1 and BRCA1 are directly involved or
regulate base excision repair, a simple parametric linear SNP-SNP association analysis, with
both SNPs coded additively, was performed. The asymptotic P value for the interaction
was .67. Due to the small sample size, the resulting sparseness in the data may render this
analysis of limited use.
Discussion
By using this unique database, an objective radiologic endpoint was available to assess
radiation sensitivity of the lungs. Radiographic abnormalities, indicative of injury, are noted
in the lung almost immediately after thoracic RT.27,37 The radiographic findings most
extensively studied are increased density on CT and decreased pulmonary perfusion on
SPECT. Radiation dose is the single most important contributor to the development of
radiographic abnormalities.38,39 An optimal endpoint to study radiation sensitivity would be
both objective and clinically relevant. SPECT abnormalities, admittedly, are only weakly
correlated with clinical outcomes, such as change in pulmonary function or development of
symptoms.40 However, radiation pneumonitis, which has also been studied in the context of
SNPs,5,14,19,22,23,41–43 is notoriously difficult to accurately identify and grade because it is a
clinical diagnosis.44 Further, although clinical symptoms are dependent on dosimetric
parameters (the volume of lung that receives a certain radiation dose), the SPECT DRC is
independent of volume. Thus, both approaches should be viewed as complementary when
studying genetic susceptibility to RT.
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In this study, when using the slope of the SPECT DRC, we observed that 2 single nucleotide
polymorphisms, one in XRCC1 and one in BRCA1, were associated with radiation
sensitivity of the lungs assessed with SPECT. In a prior analysis, the −509 promoter in the
TGFB1 gene was also associated with radiation sensitivity.26 Multiple other studies have
also observed an association among the −509 SNP in TGFB1 and radiation toxicities,
including altered breast appearance,7 breast fibrosis,8,9 erectile dysfunction,6 rectal bleeding,
and miscellaneous severe complications.10 However, several other studies have not observed
such relationships.2,45,46
The protein product of XRCC1 is involved in the base excision repair pathway in which
single-strand breaks, generated after exposure to ionizing radiation or other harmful stimuli,
are repaired. An association between radiation sensitivity and an SNP in exon 10 of XRCC1
was observed in our study (rs25487). This polymorphism substitutes an A (adenine) for G
(guanine) at messenger RNA position 1316, which leads to an amino acid substitution at
position 399 (glutamine for arginine). Patients with the ancestral allele (G) were found to be
more radiosensitive.
Yin et al14 observed that the XRCC1 Q399R AA genotype, after correcting for potential
confounding factors, was associated with a reduced risk of radiation pneumonitis in patients
with non–small-cell lung cancer (0.48) (P = .04). Andreassen et al13 observed an association
between G/G homozygotes and radiation-induced subcutaneous fibrosis after treatment for
breast cancer, with heterozygotes at intermediate risk compared with AA homozygotes.
Similarly, in a study of patients with nasopharyngeal cancer, Alsbeih et al11 noted an
association between the G allele and grade 2 to 3 late fibrosis after head-and-neck RT for
nasopharyngeal carcinoma. Chang-Claude et al47 observed a trend for a higher risk of acute
adverse effects in breast cancer patients with normal weight and with this same genetic
change, although the difference was not statistically significant.
However, Giotopoulos et al9 studied patients with breast cancer who received either
postlumpectomy or postmastectomy RT (without an electron boost) and evaluated high-
grade telangiectasias and fibrosis. SOMA score 2 to 4 telangiectasias developed in 2% of
patients with GG, 11% of patients with AG, and 5% of patients with AA. It was reported
that heterozygosity was more likely to develop telangiectasias (P = .01). Because AA
homozygotes had a lower risk than heterozygotes, the biologic significance of this is
ambiguous. Burri et al12 did not observe an association between this polymorphism and
complications after brachytherapy, with or without external-beam RT (rectal bleeding,
erectile dysfunction, urinary morbidity). Other investigators have also not found an
association between this polymorphism and subjective endpoints of radiation sensitivity,
including breast fibrosis,48 altered breast appearance after RT,2,7 and acute skin reactions.49
A pooled analysis of several studies (differing endpoints, scoring systems, patient
populations) by Langsenlehner et al50 did not observe an effect of the XRCC1 R399Q
polymorphism on risk of late radiation-induced toxicity. There was an association with
XRCC1 R280H, with an odds ratio of 0.6. We did not observe an association with this
polymorphism (P =.98), but there were only 4 heterozygotes in our population.
This is the first study, to our knowledge, that has demonstrated a possible association
between the G(3780)A SNP in BRCA1 and radiation sensitivity of the lungs. BRCA1,
typically associated with inherited breast cancer, encodes a protein that joins other proteins
involved in DNA damage recognition and repair to form a complex known as the BRCA1-
associated genome surveillance complex. BRCA1 plays a central role in repairing DNA
double-strand breaks. A lower risk of toxicity was noted in patients with the AG or GG
genotype. Few studies have evaluated BRCA1 polymorphisms and their possible
Kelsey et al. Page 6













relationship to radiation toxicity. Damaraju et al51 did not observe an association among any
BRCA1 SNPs, including position 3780, and bladder and/or rectal toxicity after pelvic RT.
We did not observe an association among many SNPs that had previously been associated
with RT toxicity (Table 4). This may be due to a lack of statistical power, lack of true
causation, or organ and/or tissue specific differences.
To date, most studies that evaluated radiation toxicity have used relatively subjective
endpoints. This is understandable because most toxicities that patients experience are not
readily quantifiable. Our study was unique because we used an objective measure of RT
sensitivity, namely dose-dependent changes in regional perfusion in the lung after thoracic
RT. We have observed possible associations between SNPs in TGFβ1, XRCC1, and
BRCA1, and a greater decline in pulmonary perfusion after RT. Large, genome-wide
association studies may ultimately be required to discover which polymorphisms are most
responsible for interpatient differences in radiation sensitivity. Ideally, objective and
clinically relevant endpoints of radiation sensitivity will be used in these endeavors.
We acknowledge the limitations of our analysis. The number of patients is small, and a
verification cohort is not available. We were constrained to use a candidate gene approach as
opposed to a genome-wide association study, given the small number of patients with
available SPECT data to perform our analysis. We also did not correct for multiple
hypotheses given the small number of patients. Thus, the associations observed could have
been due to chance alone. Finally, multivariate analyses to correct for possible confounding
factors (chemotherapy, smoking status, pulmonary function, etc) were not deemed
statistically feasible in our population. These same factors did not have a dramatic effect on
the DRC in our prior analyses.39 The fundamental and unique strength of our study, as
opposed to almost all other studies that evaluated radiation toxicity, is the objective
radiologic endpoint of radiation sensitivity that was used. In this study, in which an
objective radiologic assessment of radiation-induced lung injury was used, polymorphisms
within genes involved in repair of DNA damage (XRCC1 and BRCA1) were associated with
radiation sensitivity of the lungs.
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• Dosimetric factors predict the risk of radiation-induced lung injury but have
limitations.
• Underlying genetic factors, including SNPs, may contribute to risk.
• Further work is necessary to evaluate whether genetic factors are contributory
and how this should change clinical treatment recommendations.
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Boxplots for rs25487 (XRCC1) and rs16942 (BRCA1), Produced by Using the R Boxplot
Function With Its Default Settings, Comparing Genotype With Slope of the Single Photon
Emission Computed Tomography Dose-Response Curve. The Line in the Middle Is the
Median (Q2). The Upper and Lower Edges of the Box Are the 25th (Q1) and 75th (Q3)
Percentiles. The Height of the Box is the Interquartile Range (IQR). The Whiskers Are
Computed as Follows: Exclude All Data Points That Are Either 1.5 × IQR Below Q1 or 1.5
× IQR Above Q3. The Whiskers Correspond to the Range of This Reduced Data Set. Any
Data Points (outliers) From the Original Sample Below or Above the Whiskers Are Also
Plotted
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Table 1
Patient Characteristics (n = 39)
Characteristic
Median Age (Range), y 63 (46–87)
Sex, No. (%)
 Men 20 (51)
 Women 19 (49)
Stage, No. (%)
 I 3 (8)
 II 2 (5)
 III 27 (69)
 IV 3 (8)
 X (locally) 4 (10)
Histology, No. (%)
 Squamous 5 (13)
 Adenocarcinoma 6 (15)
 Non–small-cell not otherwise specified 24 (62)
 Small cell 4 (10)
Smoking Status, No. (%)
 Current 12 (31)
 Former 24 (61)
 Never 3 (8)
Treatment, no. (%)
 Sequential ChT/RT 22 (56)
 Concurrent ChT/RTa 10 (26)
 RT alone 7 (18)
Median Radiation Dose (range), Gy 66 (40–86.4)
Mean Lung Dose, Median (range), Gy 18.5 (5–29)
Median V20 (range) 33 (6–51)
Abbreviations: ChT = chemotherapy; RT = radiation therapy; V20 = volume of lung receiving 20 Gy or more.
a
With or without induction and/or consolidation ChT.
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Table 3
Genotype Frequencies and Association With Slope of DRCa
SNP Gene Genotypes P Value
rs2071746 HMOX1 9 AA, 22 AT, 8 TT .59
rs2071747 HMOX1 36 GG, 3 GC .67
rs2779249 NOS2A 4 AA, 23 AC, 12 CC .54
rs2297518 NOS2A 3 AA, 14 AG, 22 GG .73
rs11549465 HIF1A 27 CC, 11 CT, 1 TT .52
rs1801320 RAD51 34 GG, 5 CG .21
rs11226 RAD52 14 CC, 18 CT, 7 TT .21
rs1042522 TP53 22 GG, 17 GC .97
rs1805388 LIG4 25 CC, 13 CT, 1 TT .93
rs1062557 GRP 25 AA, 12 AC, 2 CC .18
rs1801516 ATM 1 AA, 11 AG, 27 GG .58
rs16941 BRCA1 19 AA, 15 AG, 5 GG .47
rs16942 BRCA1 19 AA, 13 AG, 7 GG .03
rs144848 BRCA2 2 GG, 15, GT, 22 TT .09
rs1799782 XRCC1 33 CC, 6 CT .24
rs25489 XRCC1 35 GG, 4 AG .98
rs25487 XRCC1 6 AA, 20 AG, 13 GG .01
rs3218536 XRCC2 1 AA, 6 AG, 32 GG .83
rs861539 XRCC3 14 CC, 18 CT, 7 TT .09
rs4880 SOD2 11 CC, 16 CT, 12 TT .98
rs13181 ERCC2 3 GG, 23 GT, 13 TT .66
rs2227928 ATR 15 CC, 19 CT, 5 TT .44
rs2229032 ATR 29 GG, 10 GA .16
rs1130409 APEX1 12 GG, 21 GT, 6 TT .27
rs26279 MSH3 17 AA, 19 AG, 3 GG .20
rs184967 MSH3 29 GG, 9 GA, 1 AA .30
rs1799977 MLH1 12 AA, 23 AG, 4 GG .15
rs3790566 IL12RB2 22 CC, 17 CT .33
rs3790567 IL12RB2 22GG, 17 GA .32
rs3790568 IL12RB2 33 GG, 6 GA .89
rs2230806 ABCA1 13 CC, 21 CT, 5 TT .60
rs2253304 ABCA1 12 GG, 21 GA, 6 AA .97
rs2487058 ABCA1 15 CC, 19 CT, 5 TT .98
Bold indicates statistically significant associations.
Abbreviations: A = adenine; C = cytosine; DRC = dose-response curve; G = guanine; SNP = single nucleotide polymorphism.
a
DRC of perfusion single photon emission computed tomography after radiation therapy.
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Table 4
SNPs Associated With Radiation Sensitivity
Gene Name SNP Endpointa
TGFB1 Transforming growth factor β1 rs1800469; rs1800470; rs1800471
Radiation pneumonitis,5 altered breast
appearance,7 breast fibrosis,7,8 erectile
dysfunction,6 rectal bleeding,6 miscellaneous
severe complications,10 neck fibrosis,11
perfusion SPECT defects26
SOD2 Superoxide dismutase 2 rs4880 Rectal bleeding,12 subcutaneous fibrosis13




XRCC3 X-ray repair cross- complementing protein3 rs861539
Acute skin reaction,15 subcutaneous fibrosis
and telangiectasia,13 severe dysphagia16
MSH2 mutS homolog 2 rs2303428 Acute skin reaction15
MSH3 mutS homolog 3 rs26279 Acute skin reaction15
ATM Ataxia telangiectasia mutated Multiple
Rectal bleeding,17 erectile dysfunction,17
urinary morbidity,17 chest wall fibrosis,18
subcutaneous late effects,52 pneumonitis,43
miscellaneous adverse reactions,53 late
effects54
MC1R Melanocortin 1 receptor Multiple Severe acute adverse effects55
FSHR Follicle-stimulating hormone receptor rs2268363 Erectile dysfunction20
P53 Tumor protein p53 rs1042522 Radiation pneumonitis19
ABCA1 ATP-binding cassette, subfamily A,member 1 rs2230806; rs2253304; rs2487058 Radiation dermatitis
21
IL12RB2 Interleukin-12 receptor, beta 2 rs379056; rs3790566; rs3790568 Radiation dermatitis21
RAD51 RAD51 homolog rs1801320 Pneumonitis23
LIG4 Ligase IV, DNA, ATP-dependent rs1805388 Pneumonitis22
Abbreviations: ATP = adenosine triphosphate; SNP = single nucleotide polymorphism; SPECT = single photon emission computed tomography.
a
Not all SNPs are associated with all endpoints.
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